Insider filing
Traded Jul 6 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
OVID · NASDAQ · Pharmaceutical Preparations
Ovid Therapeutics (OVID) · oqro.io/stocks/OVID · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.20−0.14 (−5.98%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Including 24 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded Jul 6 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 15 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Apr 7 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Apr 7 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Apr 7 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Mar 23, 2026 · largest single transaction ~$66K
Mar 23, 202647K
DetailsOfficial recordMargaret A. Alexander (President and CEO) sold ~$17K of Ovid Therapeutics
Automatic saleJeffrey A Rona (CBFO) sold ~$12K of Ovid Therapeutics
Automatic saleInsider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Feb 26, 2026 · largest single transaction 68K
Feb 26, 202668K
DetailsOfficial recordInsider filing
Traded Jan 4 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Traded Dec 15, 2025 · largest single transaction 71K
Dec 15, 202571K
DetailsOfficial recordDec 15, 202571
Traded Dec 11, 2025 · largest single transaction 71
Dec 11, 202571
DetailsOfficial recordDec 11, 202547K
Traded Dec 8, 2025 · largest single transaction 1.25M
Dec 8, 20251.25M
DetailsOfficial recordJeffrey A Rona (CBFO) sold ~$2.2K of Ovid Therapeutics
Automatic saleMargaret A. Alexander (President and COO) sold ~$3K of Ovid Therapeutics
Automatic saleInsider buying
Traded Jan 27, 2025 · filed 2 days later
Ovid Therapeutics's President and COO paid $5K out of pocket for Ovid Therapeutics shares. Shares held went up 24% with this purchase.
Mar 23, 202647K · @ $1.40
Dec 11, 202536K
DetailsOfficial recordDec 8, 20251,250
0 open-market purchases and 2 open-market sales by insiders of OVID between Apr 13, 2025 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026. The data provider lists the next release for Mar 16, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 10, 2026 | None | None | None |
| Mar 18, 2026 | 2 sales | None | None |
| Nov 12, 2025 | None | None | None |
| May 13, 2025 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies